CA2521832A1 - Heterocyclic mchr1 antagonists - Google Patents

Heterocyclic mchr1 antagonists Download PDF

Info

Publication number
CA2521832A1
CA2521832A1 CA002521832A CA2521832A CA2521832A1 CA 2521832 A1 CA2521832 A1 CA 2521832A1 CA 002521832 A CA002521832 A CA 002521832A CA 2521832 A CA2521832 A CA 2521832A CA 2521832 A1 CA2521832 A1 CA 2521832A1
Authority
CA
Canada
Prior art keywords
methyl
compound
chlorophenyl
thieno
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002521832A
Other languages
English (en)
French (fr)
Inventor
Kevin K Barvian
Andrew J Carpenter
Joel P Cooper
Paul L Feldman
Yu C Guo
Anthony L Handlon
Donald L Hertzog
Clifton E Hyman
Andrew J Peat
Gregory E. Peckham
Jason D. Speake
William R Swain
Francis X. Tavares
Huiqiang Zhou
Dulce M. Garrido
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2521832A1 publication Critical patent/CA2521832A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002521832A 2003-04-11 2004-04-06 Heterocyclic mchr1 antagonists Abandoned CA2521832A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46229203P 2003-04-11 2003-04-11
US60/462,292 2003-04-11
PCT/US2004/010518 WO2004092181A1 (en) 2003-04-11 2004-04-06 Heterocyclic mchr1 antagonists

Publications (1)

Publication Number Publication Date
CA2521832A1 true CA2521832A1 (en) 2004-10-28

Family

ID=33299933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002521832A Abandoned CA2521832A1 (en) 2003-04-11 2004-04-06 Heterocyclic mchr1 antagonists

Country Status (8)

Country Link
US (1) US20060194871A1 (US06894165-20050517-C00155.png)
EP (1) EP1618112A1 (US06894165-20050517-C00155.png)
JP (1) JP2006522812A (US06894165-20050517-C00155.png)
AR (1) AR044011A1 (US06894165-20050517-C00155.png)
CA (1) CA2521832A1 (US06894165-20050517-C00155.png)
MX (1) MXPA05010859A (US06894165-20050517-C00155.png)
TW (1) TW200510429A (US06894165-20050517-C00155.png)
WO (1) WO2004092181A1 (US06894165-20050517-C00155.png)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118320A1 (ja) 2005-04-28 2006-11-09 Takeda Pharmaceutical Company Limited チエノピリミドン化合物
WO2007011285A1 (en) * 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
KR20080048551A (ko) * 2005-09-23 2008-06-02 콜레이 파마시티컬 그룹, 인코포레이티드 1H-이미다조[4,5-c]피리딘 및 그의 유사체의 제조법
CN101273026A (zh) 2005-09-30 2008-09-24 霍夫曼-拉罗奇有限公司 作为mch受体拮抗剂的茚满衍生物
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
TW200800908A (en) * 2006-02-15 2008-01-01 Sanofi Aventis Novel azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
CN101384555A (zh) * 2006-02-15 2009-03-11 塞诺菲-安万特股份有限公司 新的氨基醇取代的芳基二氢异喹啉酮类、其制备方法以及其作为药物的用途
BRPI0712680A2 (pt) * 2006-06-08 2012-11-20 Lilly Co Eli antagonistas de receptor de mch
EP2029610A2 (en) * 2006-06-08 2009-03-04 Eli Lilly & Company Novel mch receptor antagonists
WO2008002575A1 (en) * 2006-06-26 2008-01-03 The Procter & Gamble Company Melanin concentrating hormone antagonists
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
JP2010501553A (ja) 2006-08-18 2010-01-21 アストラゼネカ アクチボラグ Mchr1アンタゴニストとしてのチエノピリミジン−4−オン誘導体およびチエノピリダジン−7−オン誘導体
CN101679348A (zh) 2007-01-10 2010-03-24 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
WO2008140239A1 (en) * 2007-05-11 2008-11-20 Korea Research Institute Of Chemical Technology Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same
BRPI0814772A2 (pt) 2007-07-21 2015-03-03 Albany Molecular Res Inc Indazóis substituídos por 5-piridinona
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
TW201040154A (en) 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted indanes, process for preparation thereof and use thereof as a medicament
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
EP2848621A4 (en) * 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC CYCLIC COMPOUND
KR101551313B1 (ko) * 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
WO2016016421A1 (en) 2014-07-31 2016-02-04 Institut Pasteur Korea 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin e synthase inhibitors
CN106866545B (zh) * 2017-03-31 2019-07-09 枣庄学院 1-环烷烃-5-硝基-1h-苯并[d]咪唑类化合物及其制备方法
CN107445899A (zh) * 2017-07-19 2017-12-08 枣庄学院 一种苯并咪唑类化合物及其制备方法
CN109020895B (zh) * 2018-08-07 2020-04-24 枣庄学院 一种金属催化的1-苄胺基取代苯并咪唑的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60142961D1 (de) * 2000-04-28 2010-10-14 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
CA2384041A1 (en) * 2000-07-05 2002-01-24 Synaptic Pharmaceuticals Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
JP2006522812A (ja) 2006-10-05
MXPA05010859A (es) 2005-12-14
WO2004092181A9 (en) 2005-01-27
AR044011A1 (es) 2005-08-24
TW200510429A (en) 2005-03-16
WO2004092181A1 (en) 2004-10-28
US20060194871A1 (en) 2006-08-31
EP1618112A1 (en) 2006-01-25

Similar Documents

Publication Publication Date Title
CA2521832A1 (en) Heterocyclic mchr1 antagonists
EP1442025B1 (en) Pyrimidinones as melanin concentrating hormone receptor 1
CA2312885C (en) 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof
US7410966B2 (en) Use of and some novel imidazopyridines
KR100297444B1 (ko) 벤즈이미다졸화합물,그들의용도및제조방법
JP5324437B2 (ja) 5−ht6モジュレーターとしてのインドール
AU660799B2 (en) 2,3 (1H,4H)-quinoxalinediones
AU2007332440A1 (en) Quinoxaline derivative
CA2740262C (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
JP2006528186A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのスルホニルジヒドロベンゾイミダゾロン化合物
CA2417082C (en) New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
FI67550C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 2,10-dihydro-4-piperazinyl-pyrazolo(3,4-b)(1,5)bensodiazepinderivat
AU2017379024A1 (en) Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine
DD255344A5 (de) Heteroaryl-oxy-beta-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
FI92203C (fi) Menetelmä terapeuttisesti aktiivisten 4-okso-imidatso/1,5-a/kinoksaliinijohdannaisten valmistamiseksi
US5466706A (en) 9H-imidazo[1,2-A]benzimidazole-3-acetamide derivatives, their preparation and their therapeutic application
CA2543627A1 (en) Sulfonyltetrahydro-3h-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
IE922342A1 (en) Imidazo[2,1-b]benzothiazole-3-acetamide derivatives, their¹preparation and their use in therapeutics
US5512590A (en) 5,6-dihydro-4h-imidazo 2',1':2,3!imidazo- 4,5,1-ij!quinoline and 4,5-dihydroimidazo- 1,2-a!pyrolo 1,2,3-cd!benzimidazole derivatives, their preparation and application in therapeutics
CA2417081C (en) New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
AU716199B2 (en) Use of tricyclic derivatives of 1,4-dihydro-1,4-dioxo-1H-nap-hthalene, novel compounds obtained and their application in therapy
AU2003230869B2 (en) 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
US20050020596A1 (en) Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands
JP2023543950A (ja) Cxcr4モジュレーターとしての環状イソチオ尿素誘導体
AU2004213458A1 (en) Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form

Legal Events

Date Code Title Description
FZDE Discontinued